CONFIDENTIAL UNTIL APRIL 1, 2025

AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline

Financing led by Venrock Healthcare Capital Partners with co-lead Forbion Growth, and participation from RTW Investments, Nextech Invest, and other new investors

Current investors ARCH Venture Partners, Forbion Ventures, ND Capital, and others also participated

AIRNA expected to file clinical trial application for Alpha-1 antitrypsin deficiency (AATD) RNA editing product candidate (AIR-001) with potential best-in-class profile in 2H 2025

Cambridge, MA, USA and Tübingen, Germany, April 1, 2025 – AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, today announced the closing of an oversubscribed $155 million Series B financing.

The financing was led by Venrock Healthcare Capital Partners, co-led by Forbion Growth, and included participation from RTW Investments, Nextech Invest, ARCH Venture Partners, Forbion Ventures, ND Capital, and other new and existing investors. AIRNA will use the proceeds to advance its lead RNA editing product candidate (AIR-001) for AATD into a Phase 1/2 clinical trial, and to develop a pipeline of novel RNA-editing medicines for cardiometabolic and other diseases.

“AIRNA is developing a new class of genetic medicines that could provide functional cures for a wide range of diseases,” said Kris Elverum, President and Chief Executive Officer of AIRNA. “This partnership of new and existing investors allows us to rapidly deliver AIR-001 to patients with AATD, as well as progress a pipeline of medicines to realize the full potential of RNA editing.”

AATD is caused by mutations in the *SERPINA1* gene that lead to insufficient levels of functional alpha-1 antitrypsin (M-AAT) protein, which results in lung and liver disease. AIR-001 precisely repairs the most common, harmful *SERPINA1* mutation (PiZ) to address the underlying cause of both lung and liver disease and restore functional M-AAT production. AIR-001 was designed for potent and durable M-AAT production, convenient, subcutaneous dosing, and well-tolerated safety to give patients a preferred therapeutic option.

“Patients with AATD have limited therapeutic options, and AIRNA is developing a potentially best-in-class medicine that has been optimized for potency, durability, and safety,” said Ken Greenberg, M.D., partner at Venrock Healthcare Capital Partners. “Venrock is thrilled to collaborate with the tremendous team at AIRNA, and a world-class investor syndicate, to bring novel RNA editing medicines to patients.”

AIRNA’s proprietary platform harnesses natural mechanisms to potently edit a target RNA with a safe and flexible medicine. Precise RNA editing has unique potential to safely introduce beneficial genetic variants that promote optimal health, in addition to repairing disease-driving mutations, such as those causing AATD. AIRNA identifies variants that drive health through human genetics, and is developing new medicines to transform the lives of patients with cardiometabolic and other diseases.

“AIRNA’s innovative approach to RNA editing has the distinctive potential to improve health across large populations by introducing healthy genetic variants for many conditions. We are excited to support the

expansion of AIRNA's pipeline of life-changing medicines and the advancement AIR-001 into the clinic," said Dirk Kersten, Managing Partner at Forbion.

Alongside this financing, AIRNA announced the appointment of Melissa McCracken, Ph.D., a partner at Nextech Invest, to the Board of Directors. Dr. McCracken has a track record of growing the next generation of innovative biopharma companies, with a focus on precision approaches.

About AIRNA
AIRNA is harnessing advances in genetics to develop transformative RNA-editing medicines that improve human health across both rare and broad populations. RNA editing offers the precision of genetic medicine approaches while maintaining treatment convenience, flexibility, and reversibility. Our proprietary platform is based on groundbreaking research by pioneers of the field and company co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University) and enables optimal potency, safety, and delivery.

AIRNA is advancing a robust pipeline of therapeutic candidates that are designed to provide functional cures for severe or chronic diseases by repairing harmful genetic variants or introducing beneficial variants promote optimal health. AIRNA's lead program has the potential to be a best-in-class therapeutic for alpha-1 antitrypsin deficiency (AATD). AIRNA has headquarters in Cambridge, MA, with research operations in Tübingen, Germany. Learn more at https://airna.com/.

Investors:
Matthew Hawryluk, PhD
Chief Business Officer
AIRNA
matthew.hawryluk@airna.com

Media:
Julie Perlin
Ten Bridge Communications
jperlin@tenbridgecommunications.com